bone morphogenetic protein-7

bone morphogenetic protein-7

A protein encoded by BMP7 on chromosome 20q13, which plays a key role in cartilage formation, osteoblast differentiation, renal development and repair, and induces the production of SMAD1.
References in periodicals archive ?
About Bone Morphogenetic Protein-7 (BMP-7) BMPs are a group of growth factors also known as cytokines and as metabologens.
is a clinical stage biopharmaceutical company whose primary focus is on utilizing Bone Morphogenetic Protein-7 to catalyze cartilage regeneration for disease modification of Osteoarthritis (OA) and the inhibition and reversal of organ fibrosis in diseases such as Chronic Kidney Disease (CKD) and Alport Syndrome.
The active ingredient, recombinant human bone morphogenetic protein-7 (rhBMP-7 or eptotermin alfa), stimulates natural bone regeneration by actively recruiting stem cells from the surrounding tissue and blood supply, initiating the bone formation cascade.
Cook SD, Baffes GC, Wolfe MW, Sampath TK, Rueger DC: Recombinant human bone morphogenetic protein-7 induces healing in a canine long-bone segmental defect model.
The mice were treated with injections of bone morphogenetic protein-7 (BMP-7), a treatment Hruska found in previous research could prevent bone weakening in mice whose kidneys had been damaged or removed.
Based on type, the global BMP market has been categorized into recombinant bone morphogenetic protein-2 (rhBMP-2) and recombinant bone morphogenetic protein-7 (rhBMP-7).
Paul Krebsbach, DDS and colleagues from the University of Michigan School of Dentistry in Ann Arbor used an adenovirus vector engineered to express bone morphogenetic protein-7 (BMP-7) to transduce human gingival or rat dermal fibroblasts.
based biopharmaceutical company, to commercialize its promising Bone Morphogenetic Protein-7 ("BMP-7") pipeline in Canada and select international markets.
a clinical stage therapeutic company focusing on Bone Morphogenetic Protein-7 and its application in Osteoarthritis (OA) and Chronic Kidney Disease (CKD), today announced that the U.
today announced that it has entered into a definitive agreement to acquire Stryker Corporation's (NYSE: SYK) Bone Morphogenetic Protein-7 (BMP-7) assets for the potential treatment of osteoarthritis (OA), chronic kidney disease (CKD) and other organ fibrosis conditions, lupus, and obesity.
Full browser ?